Tenderwize
Retour à la recherche

Non-exclusive drug discount agreement for Calcipotriol/Betamethasone foam

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline May 31, 2028 · 642 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Calcipotriol/Betamethason - Schaum (amtlicher ATC-Code: D05AX22)

30/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

30 / 100

Complexité

20 / 100

Facteurs de risque

No guaranteed demand; actual purchase volumes depend on prescription behavior and pharmacy stocking, which are unpredic...

Early termination possible if exclusive agreements are concluded (estimated 8-12 months after notice publication).

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Conclusion of non-exclusive discount agreements for pharmaceutical product Calcipotriol/Betamethasone foam (ATC D05AX22)
  • Agreement period from 4 May 2026 to 31 May 2028
Afficher le résumé complet

This is an Open-House model for non-exclusive drug discount agreements for the active substance Calcipotriol/Betamethasone (ATC D05AX22) in foam form. The AOK PLUS invites pharmaceutical companies to conclude non-exclusive discount agreements under § 130a Abs. 8 SGB V. There is no estimated value, no guaranteed purchase volumes, and no exclusivity. Submission is possible from the first deadline (30 April 2026) until the final end of the agreement (31 May 2028). The procedure is not a formal procurement under EU directive but published for transparency.

Risques

No guaranteed demand; actual purchase volumes depend on prescription behavior and pharmacy stocking, which are unpredic...

Early termination possible if exclusive agreements are concluded (estimated 8-12 months after notice publication).

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG

Administrative

  • Submission via DTVP communication function (not postal)
  • Confidentiality of tender documents and discount terms

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive drug discount agreement for Calcipotriol/Betamethasone foam

Conclusion of non-exclusive discount agreements for Calcipotriol/Betamethasone foam (ATC D05AX22) via an Open-House model. No guaranteed volumes, no minimum purchase, no exclusivity. Agreement ends no later than 31 May 2028.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

May 2026 - May 2028

Catégorie

Pharmaceutical products

Date limite

Deadline May 31, 2028

Détails de la procédure

Date de publication
26 Mar 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
213144-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30